Karcinom prostaty jako jeden z nejčastějších zhoubných nádorů a příčina smrti u mužů představuje vysoce závažný medicínský, ale i společenský a ekonomický problém. Diagnostika a následná léčba – jak kurativní, tak především léčba pokročilých stadií, včetně jejich komplikací – je proces, který je velmi náročný. Jednak pro pacienty, protože zejména časná detekce karcinomu prostaty se týká obrovské cílové skupiny mužů, jednak pro zdravotnictví, protože stále rostoucí incidence a prevalence karcinomu prostaty klade na systém nesmírné nároky organizační, personální a v neposlední řadě i ekonomické. Není možno říci, jaká je optimální léčba, protože onemocnění představuje velmi heterogenní skupinu, ale je třeba se pokusit odpovědět na otázku, jaká je optimální léčba u konkrétního pacienta a zda vzhledem ke stadiu onemocnění je ta která léčebná modalita možná a hlavně smysluplná. Autor se zaměřil na karcinom prostaty vyšších stadií a rizikových skupin a hodnotí možnosti provedení a výsledky jednotlivých léčebných modalit – radikální operace a radioterapie., Prostate cancer – one of the most common malignant tumours and cause of death in men – represents very significant medical but also social and economic problem. Diagnostics and ensuing treatment (both curative treatment and treatment of advanced stages, including associated complications) is a very complex process, not only for patients (because early detection of prostate cancer affects large numbers of men) but also for healthcare systems, because continuously increasing incidence and prevalence have significant organizational, HR and last but not at least economic demands. Owing to the heterogeneous nature of prostate cancer the optimal therapy is not clear. But we can try to determine the best treatment in an individual patient and assess if it is feasible and justified considering the individual prostate cancer stage. The author focuses on higher stage prostate cancer and higher risk groups and evaluates the feasibility and results of individual treatment options – radical surgery and radiotherapy., and Vít V., Čermák A., Pacík D.
Idiopatická plicní fibróza je onemocnění, jehož incidence a prevalence stoupá. Zobrazovací metody tvoří nedílnou součást v diagnostice tohoto fibrotizujícího plicního postižení. Stěžejní ze zobrazovacích metod je výpočetní tomografie s vysokým rozlišením. Radiologickým obrazem idiopatické plicní fibrózy je běžná intersticiální pneumonic Výpočetní tomografie s vysokým rozlišením umožňuje určit, zda jsou vyjádřeny změny typické běžné intersticiální pneumonie, možné běžné intersticiální pneumonie či změny neodpovídají běžné intersticiální pneumonii. Snaha o objektivizaci změn na výpočetní tomografii s vysokým rozlišením vedla k vytvoření jednotného skórovacího systému, který bude jednoduchý a reprodukovatelný. Klíčová slova: běžná intersticiální pneumonie, idiopatická plicní fibróza, skórování, voština, Incidence and prevalence of idiopathic pulmonary fibrosis are increasing. The integral part of diagnostics of idiopathic pulmonary fibrosis is high resolution computed tomography. Radiological image of idiopathic pulmonary fibrosis is usual interstitical pneumonia. On high resolution computed tomography are changes of typical usual interstitial pneumonia, possible usual interstitial pneumonia or signs which are not typical for usual interstitial pneumonia. There was made uniform scoring system which is quite simple and reproducible. Key words: honeycombing, idiopathic interstitial pneumonia, scoring system, usual interstitial pneumonia, Kočová E., Eliáš P., and Literatura
The PET-laboratory of the Nuclear Physics Institute ASCR, one of the first such workplaces in the world, completed research on the synthesis of extremely promising substance 3´-deoxy-3´-[18F], that has demonstrated great potential to replicate cancer tumors. and Otakar Bělohlávek, František Melichar.
A firm called Company RadioMedic Ltd., developed at the Nuclear Physics Institute of the ASCR in 2009, deals with the development, manufacturing and distribu‑ tion of radiopharmaceutical preparations. It has developed a ra-diopharmaceutical with an active substance that selectively binds to hypoxic cells. These tumor cells are more sensitive to radiotherapy and chemotherapy in the presence of oxygen in tissue and consequently the number of the hypoxic cells is a limiting factor for a therapy effect. and František Melichar.
Beside heart failure and metabolic syndrome, atrial fibrillation is termed the cardiovascular epidemic of the 21st century. Its increased morbidity and mortality is alarming. The present, most effective therapy of atrial fibrillation is catheter ablation. Successful ablation of atrial fibrillation prevents the occurrence and progression of electrical, structural and mechanic myocardium remodelling, improves function of the left ventricle, and prevents the risk of thrombembolism. Onset of sinus rhythm activates the reversal remodelling leading to wall reconstruction and atrium reduction. The paper reviews the technique and presents own experience with catheter ablation., R. Lábrová, J. Špinar, N. Honzíková., and Obsahuje bibliografii a bibliografické odkazy
This work discusses the clinical performance of chromogranin A, free metanephrine and normetanephrine determination in plasma using a radioimmunoanalytical methods for the diagnosis of pheochromocytoma and paraganglioma. Blood samples were collected from 55 patients (46 pheochromocytomas, 9 paragangliomas). A sampling of biological materials was performed preoperatively and about one week, six months and one year after adrenal gland surgery. The comparative group without a diagnosis of pheochromocytoma/paraganglioma consisted of 36 pheochromocytoma/paraganglioma patients more than 4 months after adrenal gland surgery, and of 87 patients, 16 of them with multiple endocrine neoplasia, 9 with medullary and 5 with parafolicullar carcinoma of the thyroid gland. The rest were patients with various adrenal gland disorders. Chromogranin A, metanephrine and normetanephrine were determined in the EDTA-plasma using a radioimmunoassay kits Cisbio Bioassays, France and IBL International GmbH, Germany. Clinical sensitivity was 96 % for the combination of metanephrine and normetanephrine, and 93 % for chromogranin A. Clinical specificity was 100 % for the combination metanephrine and normetanephrine, and 96 % for chromogranin A. Falsely elevated levels of chromogranin A were observed in 1 patient with chronic renal insufficiency and 9 analyses were influenced by the administration of proton pump inhibitors. These results were excluded of CGA specificity. Both the combination of plasma free metanephrine, normetanephrine and chromogranin A as determined by radioimmunoassays, which are simple without the necessity of special laboratory material, are effective markers of pheochromocytoma or paraganglioma. Chromogranin A exerts association to malignity and all markers are associated with tumor mass., R. Bílek, T. Zelinka, P. Vlček, J. Dušková, D. Michalský, K. Novák, E. Václavíková, J. Widimský Jr., and Obsahuje bibliografii
The clinical outcome of 153 Graves' disease patients treated with a wide dose range of radioactive iodine-131 (RAI) was analyzed retrospectively. Six to nine months after the first dose of RAI 60 patients (39%) were hypothyroid (or rather thyroxine-substituted) and 26 (17%) were euthyroid, while 67 patients (44%) did not respond properly: in 32 (21%) their antithyroid drug (ATD) dose could be reduced but not withdrawn (partial response) and 35 (23%) remained hyperthyroid or the same dose of ATD was necessary (no response). The outcome did not correspond significantly to the administered activity of RAI (medians 259, 259, 222, and 259 MBq for hypothyroid, euthyroid, partial, and no response subgroups, respectively), or the activity retained in the gland at 24 h (medians 127, 105, 143, and 152 MBq). The effect was, however, clearly, and in a stepwise pattern, dependent on initial thyroid volume (17, 26, 33 and 35 ml, P < 0.001) or activity per gram tissue retained at 24 h (6.02, 4.95, 4.75, and 4.44 MBq/g, P = 0.002). Also, higher residual level of thyrotoxicosis at the time of RAI treatment was connected with worse outcome. The dose-dependency of outcome was further analyzed. When our sample was divided into tertiles, according to the adjusted dose, the same modest success rates (47%) were seen in the lower and middle tertiles. However, doses higher than 5.88 MBq/g (the upper tertile) resulted in success rate of 75%. Finer division into decils has shown a threshold-like increase in cure rate between the 7th and the 8th decil. In the first 7 decils (doses ≤ 6 MBq/g) the complete response rate was 45 to 50%, in the 8th decil (6.0 to 7.8~MBq/g) it rose to 80% and was not further increased with increasing dose. Direct comparison of higher (> 6 MBq/g, cure rate 80%) and lower (≤ 6 MBq/g, cure rate 46%) doses gave highly significant difference (P < 0.001). With our dosing range we found a dose-dependent clinical outcome that suggests an optimum delivered dose near 6.5 MBq/g, resulting in successful treatment of ca 80% patients. and J. Čepková, J. Horáček, J. Vižďa, J. Doležal